White Paper

Breakthrough Therapy Designation And Accelerated Approval With Inadequate CMC Program Development: Hurry Up And Wait

Source: Rho

By Scott Burian, Ph.D., Kevin Barber, Ph.D., David Shoemaker, Ph.D.

Clinical Trial Transparency: The Technology Imperative

This article examines the development and marketing application review processes for the chemistry, manufacturing, and controls (CMC) aspects of products targeting serious conditions in the context of the FDA’s expedited accelerated approval (AA) and breakthrough therapy designation (BTD) programs. Inasmuch as these expedited programs were primarily developed to accelerate clinical development with little to no regard for accompanying manufacturing requirements, companies often find themselves having completed their clinical programs far in advance of the development of an adequate CMC program to support a marketing application. This article presents strategies for accelerating your CMC program in an attempt to complete your clinical and CMC development simultaneously in order to maximize the benefit of these expedited programs.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: